Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$26.50 USD
+0.08 (0.30%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $26.49 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 101 - 120 ( 290 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Novel Compounds to Treat ATTR Amyloidosis Appear on Track to Generate Peak Annual Revenues of $50B-Plus
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Wedbush Monthly Check-Up: April 2022
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Weakness in Intellia Shares Driven by IP Concerns are Overdone; Presents Buying Opportunity, in Our View
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Interim Phase 1 Data Affirms Durable Serum TTR Reductions for In Vivo Genome Editing Candidate Therapy, NTLA-2001
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia''s First Ex Vivo Clinical Program, NTLA-5001 Kicks Into High Gear; First AML Patient Dosed in Phase 1/2a Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dose-Dependent Pathogenic Serum Protein Reduction with ATTR Therapy
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Results; Additional Readout for ATTRv-PN; In Vivo Development Candidate for AATD; Broadening Cell Therapy Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q21: Additional Data From Lead Program on Feb 28th
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia and ONK Therapeutics Join Forces to Develop Allogeneic CRISPR-Edited NK Cell Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Twin Studies Published in Science Translational Medicine Support Efficacy of Targeting WT-1 Epitopes in Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T